Investigators evaluated the antitumor activity of infigratinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 alterations.
Investigators evaluated the antitumor activity of infigratinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma and FGFR2 alterations.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
